Washington — Supreme Court Keeps Trans Inmate Care in Place

The US Supreme Court on Oct. 21, 2026, refused to let President Donald Trump's administration cut off hormone treatments and social accommodations for roughly 1,000 transgender federal inmates, according to Bloomberg. The order leaves in place care that includes hormone therapy and items such as wigs and makeup while litigation over the policy continues.

The ruling is described by Bloomberg as a rare setback for the administration on transgender rights, a policy area where Trump has largely prevailed in court and through executive action since returning to office. For the roughly 1,000 inmates affected, the decision means current treatment protocols stay in effect rather than being terminated immediately.

What did the administration ask the justices to do?

According to Bloomberg's reporting, the Trump administration sought Supreme Court permission to end the hormone treatments and accommodations that had been provided to transgender inmates in federal custody. The justices declined that request, meaning the administration cannot move forward — for now — with cutting off the care in question. Bloomberg's dispatch does not detail the administration's underlying legal argument, the specific case name, or the vote breakdown among the justices, and no additional court filings were provided in the source material reviewed for this report.

Who is affected by the order?

The population at issue is described in Bloomberg's reporting as approximately 1,000 transgender inmates held in federal custody. The care covered by the order spans two categories: hormone treatments, which are medical, and social accommodations such as wigs and makeup, which the report characterizes separately from the medical component. Bloomberg's account does not break down how many inmates receive each type of accommodation or specify which federal facilities are involved.

Why is this notable now?

Bloomberg frames the order as a rare loss for Trump specifically because his administration has otherwise had considerable success narrowing transgender rights policy through the courts and executive action during his current term. A Supreme Court refusal to grant the administration's request — rather than an outright ruling on the merits of the underlying policy — still functions as an immediate practical check: the treatments and accommodations continue rather than ending while the broader legal fight plays out.

The order does not resolve the underlying dispute over whether the federal government is required, or merely permitted, to provide such care to inmates. It addresses only whether the administration could end the care now, before further proceedings. That distinction matters for how the ruling should be read: it preserves a status quo rather than declaring a final legal standard.

What isn't yet known about the ruling?

Bloomberg's published account, the only sourcing available for this report, does not include the text of the Supreme Court's order, whether any justices dissented publicly, or whether the order was accompanied by a written opinion. It also does not identify the lower court proceeding that the emergency application arose from, nor does it quote directly from either the administration's filing or any response from inmates' counsel. Readers looking for the full record will need to consult the Supreme Court's docket directly once it is made public, as no link to the underlying filings was included in the reporting reviewed here.

What happens next?

Because the Supreme Court's action blocks the administration's bid rather than settling the dispute outright, the litigation is expected to continue in the lower courts. Bloomberg's report does not specify a timeline for further proceedings or indicate whether the administration intends to pursue the matter again once additional briefing or a lower-court ruling is in hand. Until then, the hormone treatments and accommodations described in the order remain in place for the inmates covered by it.

The case adds to a broader set of legal fights over federal policy toward transgender individuals that have moved through the courts this year, though Bloomberg's account treats this particular order as a standalone development rather than part of a consolidated case list. Further details — including any formal opinion, case caption, or scheduling order — were not available in the material reviewed for this report.